ipriflavone has been researched along with Osteoporosis in 46 studies
ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty patients with post-menopausal osteoporosis were randomly divided into two groups of ten patients and treated under double-blind conditions with ipriflavone (Osteofix) or placebo." | 9.06 | Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. ( Agnusdei, D; Bigazzi, S; Cepollaro, C; Gennari, C; Montagnani, M; Nardi, P; Zacchei, F, 1989) |
| "Siberian ginseng extract produced a protective effect during experimental steroid-induced osteoporosis, which was comparable with the influence of ipriflavone." | 7.71 | Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis. ( Koldaev, VM; Kolodnyak, OL; Kropotov, AV, 2002) |
| "In order to evaluate the effect of Ipriflavone (BO, synthesized for the first time by the School of Pharmaceutical Sciences of WCUMS) against osteoporosis in ovariectomized (OVX) rats, 98 female Wistar rats were divided into 7 groups: bilateral OVX, sham operated (S), and 5 treatment groups after OVX, of which 3 groups were given domestic BO-25, 100, and 400 mg/kg BW (L, M, H), respectively, and the remaining two groups, BO (made in Japan)-100 mg/kg BW (J) and 17 beta-estradiol-4 mg/kg BW (E)." | 7.69 | [Experimental study on the effect of ipriflavone against osteoporosis in ovariectomized rats]. ( Li, H; Ouyang, Q; Weng, L; Zheng, Z, 1994) |
| "The purpose of these experiments was to study the effect of Ipriflavone (7 isopropoxy-isoflavone) on the osteoporosis induced by immobilization." | 7.67 | The effect of ipriflavone treatment on osteoporosis induced by immobilization. ( Földes, I; Gyarmati, J; Rapcsák, M; Szilágyi, T; Szöör, A, 1988) |
| "Ipriflavone, 7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one, was administered orally for 12 weeks to male rats with prednisolone-induced osteoporosis." | 7.67 | Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. ( Kinoshita, M; Shimizu, Y; Shino, A; Shirakawa, Y; Tsukuda, R; Yamazaki, I, 1986) |
| "Its effect of hindering bone resorption works presumably also this way." | 5.28 | [A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets]. ( Bossányi, A; Bucsi, L, 1989) |
| "Twenty patients with post-menopausal osteoporosis were randomly divided into two groups of ten patients and treated under double-blind conditions with ipriflavone (Osteofix) or placebo." | 5.06 | Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. ( Agnusdei, D; Bigazzi, S; Cepollaro, C; Gennari, C; Montagnani, M; Nardi, P; Zacchei, F, 1989) |
| "Ipriflavone, an isoflavone synthesized from the soy isoflavone daidzein, holds great promise in the prevention and treatment of osteoporosis and other metabolic bone diseases." | 4.80 | Ipriflavone: an important bone-building isoflavone. ( Head, KA, 1999) |
| "Siberian ginseng extract produced a protective effect during experimental steroid-induced osteoporosis, which was comparable with the influence of ipriflavone." | 3.71 | Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis. ( Koldaev, VM; Kolodnyak, OL; Kropotov, AV, 2002) |
| "In order to evaluate the effect of Ipriflavone (BO, synthesized for the first time by the School of Pharmaceutical Sciences of WCUMS) against osteoporosis in ovariectomized (OVX) rats, 98 female Wistar rats were divided into 7 groups: bilateral OVX, sham operated (S), and 5 treatment groups after OVX, of which 3 groups were given domestic BO-25, 100, and 400 mg/kg BW (L, M, H), respectively, and the remaining two groups, BO (made in Japan)-100 mg/kg BW (J) and 17 beta-estradiol-4 mg/kg BW (E)." | 3.69 | [Experimental study on the effect of ipriflavone against osteoporosis in ovariectomized rats]. ( Li, H; Ouyang, Q; Weng, L; Zheng, Z, 1994) |
| " In this study, to determine if KCA-098 is therapeutically applicable for the treatment of osteoporosis, we compared the effect of KCA-098 on bone tissues with that of ipriflavone, a drug that is clinically used for the treatment of osteoporosis." | 3.69 | Effects of KCA-098 on bone metabolism: comparison with those of ipriflavone. ( Arai, N; Endo, H; Itoh, F; Kawashima, K; Kojima, M; Nagata, H; Tsutsumi, N; Tsuyuki, J; Ujiie, A, 1994) |
| "The purpose of these experiments was to study the effect of Ipriflavone (7 isopropoxy-isoflavone) on the osteoporosis induced by immobilization." | 3.67 | The effect of ipriflavone treatment on osteoporosis induced by immobilization. ( Földes, I; Gyarmati, J; Rapcsák, M; Szilágyi, T; Szöör, A, 1988) |
| "Ipriflavone, 7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one, was administered orally for 12 weeks to male rats with prednisolone-induced osteoporosis." | 3.67 | Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. ( Kinoshita, M; Shimizu, Y; Shino, A; Shirakawa, Y; Tsukuda, R; Yamazaki, I, 1986) |
| " Ipriflavone efficaciously alleviated the adverse effects of estrogen deficiency such as bone loss and increase in LDL-C level, and the ability of leuprolide therapy to reduce myoma volume was not decreased by ipriflavone administration." | 2.70 | Efficacy of ipriflavone in preventing adverse effects of leuprolide. ( Aso, T; Chiguchi, M; Ishibashi, T; Somekawa, Y; Wakana, K, 2001) |
| "Ipriflavone is an original molecule." | 2.39 | [The ipriflavone story]. ( György, L; István, H; Marian, EP; Mihály, N, 1995) |
| "Ipriflavone was ineffective in restoring bone density and unlike estrogen did not prevent bone resorption as evidenced by increased (p < 0." | 1.33 | Ipriflavone modulates IGF-I but is unable to restore bone in rats. ( Arjmandi, BH; Devareddy, L; Deyhim, F; Juma, S; Smith, BJ; Soung, DY, 2005) |
| "Osteoporosis was determined by the extent of bone density and by lowering the concentrations of serum Ca2+, P and ALP activity every week." | 1.32 | Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats. ( Kim, SK; Lee, MH; Rhee, MH, 2003) |
| "Ipriflavone treatment was not associated with significant changes in serum alkaline phosphatase nor type I collagen telopeptide levels, two markers of bone turnover." | 1.29 | Ipriflavone improves bone density and biomechanical properties of adult male rat bones. ( Abbasi-Jarhomi, SH; Civitelli, R; Dimarogonas, A; Halstead, LR, 1995) |
| "Ipriflavone is a recently introduced anti-osteoporotic agent extensively metabolized to four major metabolites (M1, M2, M3, M5)." | 1.28 | Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure. ( Acerbi, D; Rondelli, I; Ventura, P, 1991) |
| "Its effect of hindering bone resorption works presumably also this way." | 1.28 | [A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets]. ( Bossányi, A; Bucsi, L, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.70) | 18.7374 |
| 1990's | 27 (58.70) | 18.2507 |
| 2000's | 13 (28.26) | 29.6817 |
| 2010's | 1 (2.17) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Zheng, A | 1 |
| Xin, XZ | 1 |
| Peng, LJ | 1 |
| Wang, J | 1 |
| Cao, LY | 1 |
| Jiang, XQ | 1 |
| Radzki, RP | 1 |
| Bieńko, M | 1 |
| Filip, R | 1 |
| Pierzynowski, SG | 1 |
| Kropotov, AV | 1 |
| Kolodnyak, OL | 1 |
| Koldaev, VM | 1 |
| Perugini, P | 1 |
| Genta, I | 1 |
| Conti, B | 1 |
| Modena, T | 1 |
| Cocchi, D | 1 |
| Zaffe, D | 1 |
| Pavanetto, F | 1 |
| Kim, SK | 1 |
| Lee, MH | 1 |
| Rhee, MH | 1 |
| Deyhim, F | 1 |
| Smith, BJ | 1 |
| Soung, DY | 1 |
| Juma, S | 2 |
| Devareddy, L | 1 |
| Arjmandi, BH | 2 |
| Anderson, DC | 1 |
| Scoggins, BP | 1 |
| Fiore, CE | 1 |
| Gibilaro, M | 1 |
| Motta, M | 1 |
| Foti, R | 1 |
| Dieli, M | 1 |
| Civitelli, R | 3 |
| Abbasi-Jarhomi, SH | 1 |
| Halstead, LR | 1 |
| Dimarogonas, A | 1 |
| Ouyang, Q | 1 |
| Li, H | 1 |
| Zheng, Z | 1 |
| Weng, L | 1 |
| Bucsi, L | 2 |
| Ashton, BA | 1 |
| Tsutsumi, N | 1 |
| Kawashima, K | 1 |
| Nagata, H | 1 |
| Tsuyuki, J | 1 |
| Itoh, F | 1 |
| Arai, N | 1 |
| Kojima, M | 1 |
| Ujiie, A | 1 |
| Endo, H | 1 |
| Miki, T | 1 |
| Morii, H | 2 |
| Fujita, T | 1 |
| Böcskei, Z | 1 |
| Simon, K | 1 |
| Varga, M | 1 |
| Hermecz, I | 1 |
| György, L | 1 |
| Mihály, N | 1 |
| Marian, EP | 1 |
| István, H | 1 |
| Attila, BK | 1 |
| Zsuzsanna, B | 1 |
| Rodionova, SS | 1 |
| Pellicano, M | 1 |
| Morgera, R | 1 |
| Affinito, P | 1 |
| Di Carlo, C | 1 |
| Napolitano, V | 1 |
| Merlino, P | 1 |
| Tremolaterra, F | 1 |
| Palomba, S | 1 |
| Nappi, C | 1 |
| Reginster, JY | 1 |
| Taquet, AN | 1 |
| Gosset, C | 1 |
| Shiota, E | 1 |
| Nozaki, M | 1 |
| Hashimoto, K | 1 |
| Inoue, Y | 2 |
| Ogata, R | 1 |
| Okuma, A | 1 |
| Nakano, H | 1 |
| Head, KA | 1 |
| Ohishi, T | 1 |
| Koide, Y | 1 |
| Takahashi, M | 1 |
| Oikawa, M | 1 |
| Kushida, K | 1 |
| Panteliou, SD | 1 |
| Abbasi-Jahromi, H | 1 |
| Dimarogonas, AD | 1 |
| Kohrt, W | 1 |
| Birnbaum, RS | 1 |
| Barengolts, E | 1 |
| Kukreja, SC | 1 |
| Somekawa, Y | 1 |
| Chiguchi, M | 1 |
| Ishibashi, T | 1 |
| Wakana, K | 1 |
| Aso, T | 1 |
| Tsourounis, C | 1 |
| Katase, K | 1 |
| Kato, T | 1 |
| Hirai, Y | 1 |
| Hasumi, K | 1 |
| Chen, JT | 1 |
| Moyad, MA | 1 |
| Ishii, J | 1 |
| Makita, K | 1 |
| Ohta, H | 1 |
| Passeri, M | 1 |
| Biondi, M | 1 |
| Costi, D | 1 |
| Bufalino, L | 1 |
| Castiglione, GN | 1 |
| Di Peppe, C | 1 |
| Abate, G | 1 |
| Nakamura, S | 1 |
| Morimoto, S | 1 |
| Takamoto, S | 1 |
| Onishi, T | 1 |
| Fukuo, K | 1 |
| Koh, E | 1 |
| Kitano, S | 1 |
| Miyashita, Y | 1 |
| Yasuda, O | 1 |
| Tamatani, M | 1 |
| Rondelli, I | 1 |
| Acerbi, D | 1 |
| Ventura, P | 1 |
| Kaneko, T | 1 |
| Bossányi, A | 1 |
| Agnusdei, D | 1 |
| Zacchei, F | 1 |
| Bigazzi, S | 1 |
| Cepollaro, C | 1 |
| Nardi, P | 1 |
| Montagnani, M | 1 |
| Gennari, C | 1 |
| Földes, I | 1 |
| Rapcsák, M | 1 |
| Szöör, A | 1 |
| Gyarmati, J | 1 |
| Szilágyi, T | 1 |
| Yamazaki, I | 1 |
| Shino, A | 1 |
| Shimizu, Y | 1 |
| Tsukuda, R | 1 |
| Shirakawa, Y | 1 |
| Kinoshita, M | 1 |
12 reviews available for ipriflavone and Osteoporosis
| Article | Year |
|---|---|
[Clinical aspects of calcium metabolism disorders of the bone. II. Progress in diagnosis and treatment. 2. Metabolic diseases of the bone: 4) Prevention and treatment of osteoporosis].
Topics: Calcitonin; Calcium; Estrogen Replacement Therapy; Female; Humans; Isoflavones; Osteoporosis; Vitami | 1993 |
[The ipriflavone story].
Topics: Angina Pectoris; Animal Feed; Animals; Food, Fortified; Humans; Isoflavones; Molecular Structure; Os | 1995 |
[Overview of clinical studies with ipriflavone].
Topics: Clinical Trials as Topic; Humans; Hungary; Isoflavones; Japan; Osteoporosis | 1995 |
[Place of ipriflavone in the therapy of osteoporosis].
Topics: Controlled Clinical Trials as Topic; Estrogen Replacement Therapy; Female; Humans; Isoflavones; Oste | 1995 |
In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; H | 1997 |
[Diagnosis, therapy and nutrition management of osteoporosis].
Topics: Analgesics; Bone Density; Calcitonin; Cholecalciferol; Dietary Proteins; Diphosphonates; Estrogen Re | 1998 |
Therapy for osteoporosis. Miscellaneous and experimental agents.
Topics: Anabolic Agents; Humans; Insulin-Like Growth Factor I; Isoflavones; Osteoporosis; Parathyroid Hormon | 1998 |
Ipriflavone: an important bone-building isoflavone.
Topics: Bone Remodeling; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism; Isoflavones; Osteit | 1999 |
Clinical effects of phytoestrogens.
Topics: Bone Density; Breast Neoplasms; Cholesterol; Estrogens, Non-Steroidal; Female; Hormone Replacement T | 2001 |
Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research.
Topics: Aged; Aged, 80 and over; Calcium; Complementary Therapies; Dietary Supplements; Female; Gonadotropin | 2002 |
[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
Topics: Alendronate; Calcitonin; Clinical Trials as Topic; Drug Approval; Estriol; Etidronic Acid; Europe; H | 2002 |
[Ipriflavone in the treatment of osteoporosis].
Topics: Animals; Bone Density; Bone Remodeling; Clinical Trials as Topic; Femoral Neck Fractures; Fractures, | 2002 |
9 trials available for ipriflavone and Osteoporosis
| Article | Year |
|---|---|
[Modification of cortical and trabecular mineral density of the femur, induced by ipriflavone therapy, Clinical results after 12 months].
Topics: Adult; Aged; Bone Density; Bone Resorption; Female; Femoral Fractures; Femoral Neck Fractures; Femur | 1995 |
[The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis].
Topics: Aged; Analgesics; Bone Density; Bone Remodeling; Female; Humans; Isoflavones; Male; Middle Aged; Ost | 1995 |
[Effects of ipriflavone on bone loss induced by GnRH analog].
Topics: Analgesics; Antineoplastic Agents, Hormonal; Bone Remodeling; Female; Genital Diseases, Female; Geni | 1996 |
Evaluation of the drug therapy for established osteoporosis by dual-energy x-ray absorptiometry.
Topics: Absorptiometry, Photon; Bone Density; Calcitonin; Calcium Compounds; Female; Humans; Hydroxycholecal | 1998 |
Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
Topics: Absorptiometry, Photon; Adult; Amino Acids; Analgesics; Bone Density; Bone Remodeling; Drug Therapy, | 1998 |
Efficacy of ipriflavone in preventing adverse effects of leuprolide.
Topics: Adult; Bone Density; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estrogen Antagonists; Female; | 2001 |
Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
Topics: Bone Density; Bone Remodeling; Female; Humans; Isoflavones; Menopause; Middle Aged; Osteoporosis; Os | 2001 |
Effect of ipriflavone on bone mass in elderly osteoporotic women.
Topics: Aged; Aged, 80 and over; Bone Density; Creatinine; Double-Blind Method; Female; Humans; Hydroxyproli | 1992 |
Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Topics: Bone and Bones; Clinical Trials as Topic; Double-Blind Method; Female; Flavonoids; Humans; Isoflavon | 1989 |
25 other studies available for ipriflavone and Osteoporosis
| Article | Year |
|---|---|
Osteogenic Induction of Low-dose Ipriflavone on Bone Marrow Mesenchymal Stem Cells Extracted from Osteoporosis Rats.
Topics: Animals; Cells, Cultured; Isoflavones; Mesenchymal Stem Cells; Osteogenesis; Osteoporosis; Rats | 2021 |
The Protective and Therapeutic Effect of Exclusive and Combined Treatment with Alpha-ketoglutarate Sodium Salt and Ipriflavone on Bone Loss in Orchidectomized Rats.
Topics: Animals; Humans; Isoflavones; Ketoglutaric Acids; Male; Orchiectomy; Osteoporosis; Rats; Rats, Wista | 2016 |
Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis.
Topics: Animals; Eleutherococcus; Glucocorticoids; Isoflavones; Male; Osteoporosis; Plant Extracts; Rats; Ra | 2002 |
PLGA microspheres for oral osteopenia treatment: preliminary "in vitro"/"in vivo" evaluation.
Topics: Animals; Bone Remodeling; Disease Models, Animal; Drug Carriers; Drug Compounding; Female; Injection | 2003 |
Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats.
Topics: Alkaline Phosphatase; Animals; Antlers; Bone Density; Bone Remodeling; Calcium; Dietary Supplements; | 2003 |
Ipriflavone modulates IGF-I but is unable to restore bone in rats.
Topics: Animals; Blotting, Northern; Bone Remodeling; Female; Femur; Insulin-Like Growth Factor I; Isoflavon | 2005 |
Potential ipriflavone and warfarin interaction.
Topics: Aged; Anticoagulants; Complementary Therapies; Contraindications; Drug Interactions; Female; Humans; | 2007 |
Ipriflavone improves bone density and biomechanical properties of adult male rat bones.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Biomarkers; Biomechanical Phenomena; Bone Densi | 1995 |
[Experimental study on the effect of ipriflavone against osteoporosis in ovariectomized rats].
Topics: Alkaline Phosphatase; Animals; Bone Density; Bone Resorption; Calcium; Female; Isoflavones; Osteopor | 1994 |
[Comparative study of the in vitro effects of calcitonin, NaF and ipriflavone in cell culture].
Topics: Bone Density; Bone Resorption; Calcitonin; Cells, Cultured; Fibroblasts; Humans; In Vitro Techniques | 1994 |
Effects of KCA-098 on bone metabolism: comparison with those of ipriflavone.
Topics: 24,25-Dihydroxyvitamin D 3; Animals; Bone and Bones; Bone Density; Bone Resorption; Calcification, P | 1994 |
[Diagnosis and therapy of osteoporosis].
Topics: Bone Density; Calcitonin; Calcium; Diagnosis, Differential; Exercise; Female; Humans; Isoflavones; M | 1993 |
Ipriflavone, an antiostheophorotic agent.
Topics: Analgesics; Crystallography, X-Ray; Isoflavones; Molecular Structure; Osteoporosis | 1996 |
A case of femoral neck fracture in a patient with severe testosterone deficiency.
Topics: Aged; Bone Density; Calcitonin; Femoral Neck Fractures; Humans; Hydroxycholecalciferols; Hypogonadis | 1999 |
Low-frequency acoustic sweep monitoring of bone integrity and osteoporosis.
Topics: Absorptiometry, Photon; Acoustic Stimulation; Analgesics; Animals; Bone and Bones; Bone Density; Dis | 1999 |
The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms.
Topics: Alkaline Phosphatase; Animals; Blotting, Western; Body Weight; Bone Density; Bone Remodeling; Eating | 2000 |
Ipriflavone.
Topics: Humans; Isoflavones; Osteoporosis | 2000 |
Ipriflavone: A New Non-Hormonal Therapeutic Agent in Osteoporosis. Satellite symposium proceedings. Florence, Italy, April 24, 1992.
Topics: Animals; Humans; Isoflavones; Osteoporosis | 1992 |
Proceedings from a symposium of basic research on ipriflavone (Osten). Yokohama, Japan. January 18, 1992.
Topics: Animals; Bone and Bones; Humans; Isoflavones; Osteoporosis | 1992 |
Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density; Calcitonin; Calcitriol; Calcium; Female | 1992 |
Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.
Topics: Adult; Aged; Female; Humans; Isoflavones; Kidney Failure, Chronic; Male; Middle Aged; Osteoporosis | 1991 |
[Osteoporosis in diabetes mellitus].
Topics: Adult; Aged; Calcitonin; Diabetes Complications; Female; Humans; Isoflavones; Japan; Male; Middle Ag | 1990 |
[A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].
Topics: Aged; Aged, 80 and over; Bone Resorption; Estrogens; Female; Flavonoids; Humans; Isoflavones; Middle | 1989 |
The effect of ipriflavone treatment on osteoporosis induced by immobilization.
Topics: Aging; Animals; Bone and Bones; Bone Development; Flavonoids; Immobilization; Isoflavones; Male; Ost | 1988 |
Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Bone and Bones; Calcitonin; Calcium; Flavonoids; Isoflavones; Male; Minerals; Osteoporosis; | 1986 |